25
Sep-2017
Sep-2017
Fusion Pharmaceuticals Completes Oversubscribed Series A Financing Totaling $46 Million USD to Develop Targeted Alpha Therapeutics
Fusion Pharmaceuticals, a Hamilton-based clinical-stage biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, announced it has completed a second closing of its Series A financing, securing an additional $21 million USD in capital and bringing the total capital raised to $46 million USD.
Fusion Pharmaceuticals is a spinout from the Centre for Probe Development and Commercialization (CPDC), which is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University
To read the full press release, click here